All Deals
September 3, 2025 - Deals
Greenoaks Capital Leads $350 Million Funding Round For AI Startup Sierra Valued At $10 Billion
Sierra, the AI startup founded by former Salesforce co-CEO and current OpenAI chair Bret Taylor and former Google exec Clay Bavor, is nearing a $350 million funding round led by Greenoaks Capital that would value the two-year-old company at $10 billion. The company, which builds custom AI agents for enterprise customer service, previously raised $175 million at a $4.5 billion valuation last October and is now on track to surpass $100 million in enterprise annual recurring revenue.
INVESTOR: Greenoaks Capital
AMOUNT: $350,000,000
HQ: #SanFrancisco #California
#VentureCapital #Sierra #BretTaylor #ClayBavor #GreenoaksCapital #TradedVC
More Deals
View All
Netflix Acquires AI Filmmaking Startup InterPositive For $587 MillionNetflix confirmed that it paid approximately $587 million in cash to acquire InterPositive, the AI filmmaking startup founded by Ben Affleck, according to a recent SEC filing. Founded in 2022 and previously operating largely in stealth mode as Fin Bone LLC, InterPositive developed AI-powered post-production tools that help filmmakers correct continuity issues, enhance visual effects, relight scenes, and streamline editing workflows without generating content from scratch. As part of the acquisition, the entire InterPositive team joined Netflix, while Affleck will remain involved as a senior technology adviser. The confirmed purchase price aligns closely with earlier reports that valued the deal at up to $600 million, making it one of Netflix’s largest acquisitions as the company continues expanding its use of AI across film and television production.
SALE PRICE: $587,000,000
HQ: Los Gatos, California
#VentureCapital #Netflix #BenAffleck #InterPositive #TradedVC
Jasper Therapeutics Acquires Kira Pharmaceuticals For $132 Million With Investment From Affinity Asset Advisors And Ikarian CapitalJasper Therapeutics has completed its all-stock acquisition of Kira Pharmaceuticals and secured approximately $132 million in new capital through a private placement, creating a combined immunology-focused biotech company with a three-asset pipeline. The financing was co-led by Affinity Asset Advisors and Ikarian Capital, with participation from several institutional investors, and is expected to support operations through the second half of 2028. The merged company will advance programs including KP-104, briquilimab, and KP-701, while Kira has also out-licensed two additional assets to Mirador Therapeutics in a deal that includes upfront, milestone, and royalty payments. Jasper CEO Jeet Mahal will continue to lead the combined company, which will remain listed on Nasdaq under the ticker JSPR.
SALE PRICE: $132,000,000
HQ: Redwood City, California
#VentureCapital #JasperTherapeutics #KiraPharmaceuticals #TradedVC